三维DNA结构改变驱动IDH1与DNMT3A突变急性髓系白血病的独特白血病特征
该研究利用携带IDH1 p.R132H或DNMT3A p.R882H突变的细胞模型及原发AML样本,通过HiC和RNA测序分析突变特异性三维DNA结构及转录改变。发现两种突变AML存在共享和独特的区室化及DNA环形成变化,与差异基因表达相关;IDH1突变AML中环介导的IGF1R上调对应IGF1R抑制剂BMS-754807的敏感性,DNMT3A突变AML对p38/MAPK抑制剂ralimetinib敏感。
要点
- IDH1和DNMT3A突变AML存在共享和独特的3D-DNA结构改变,与差异转录相关
- IDH1突变AML中环介导的IGF1R上调,对IGF1R抑制剂BMS-754807敏感
- DNMT3A突变AML对p38/MAPK抑制剂ralimetinib敏感
核心结论
- IDH1和DNMT3A突变AML具有共享和独特的3D-DNA结构改变,驱动差异转录并揭示治疗脆弱性。
研究设计与样本
- 使用携带IDH1 p.R132H或DNMT3A p.R882H突变的细胞模型及原发AML样本。
- 通过HiC分析突变特异性3D-DNA结构,通过RNA测序分析转录改变。
主要发现
- 在IDH1和DNMT3A突变AML中鉴定出区室化和DNA环形成的共享及独特变化,与差异基因表达相关。
- IDH1突变AML中鉴定出环介导的IGF1R上调,对应IGF1R抑制剂BMS-754807单药及与ivosidenib联合的敏感性。
- DNMT3A突变AML对p38/MAPK抑制剂ralimetinib敏感。
关键数值与推荐
- IDH1突变AML对IGF1R抑制剂BMS-754807单药及与ivosidenib联合敏感。
- DNMT3A突变AML对p38/MAPK抑制剂ralimetinib敏感。
临床怎么用
- IDH1突变AML可考虑IGF1R抑制剂BMS-754807单药或联合ivosidenib治疗策略。
- DNMT3A突变AML可考虑p38/MAPK抑制剂ralimetinib治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute myeloid leukemia (AML) is characterized by complex molecular alterations including mutations in epigenetic regulators such as IDH1 and DNMT3A, which are associated with globally altered DNA methylation affecting gene transcription, treatment choices, and outcomes. Additionally, IDH1 mutations are linked to changes in DNA-loop formation leading to oncogene upregulation. Here, we assessed 3D-DNA conformational changes in IDH1- and DNMT3A-mutated (mut) AML on a genome-wide scale as a global driver of leukemic signaling to identify novel therapeutic vulnerabilities. Using a cellular model with either IDH1 p.R132H or DNMT3A p.R882H mutation and primary AML samples, we analyzed mutation-specific 3D-DNA architecture by chromatin-conformation-capture (HiC) and transcriptional alterations by RNA sequencing. We identified both shared and distinct changes in compartmentalization and underlying DNA-loop formation in both DNMT3A- and IDH1-mut AML, which were linked to differential gene expression, supporting that 3D-genome architecture broadly influences transcription. Thereby, loop-mediated upregulation of IGF1R was identified in IDH1-mut AML, corresponding to specific sensitivity to IGF1R inhibitor BMS-754807 as mono- and combination therapy with ivosidenib, while DNMT3A-mut AML exhibited sensitivity to p38/MAPK inhibitor ralimetinib. Our data present a comprehensive map of global 3D-DNA alterations associated with IDH1- and DNMT3A mutations as a basis for further assessment of novel therapeutic strategies for both AML entities.
引用
- Steinhäuser S, Sreenivasan VKA, Baden D, et al. Alterations in 3D-DNA architecture drive unique leukemic profiles in IDH1- and DNMT3A-mutant acute myeloid leukemia. Leukemia. 2026. PMID: 42823507. doi:10.1038/s41375-026-03152-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。